Emergent Technologies’ portfolio company, Receptor Logic, has entered into an exclusive License Agreement providing Xencor, Inc. with exclusive worldwide rights to use a T-Cell Receptor Mimic (TCRm) monoclonal antibody against the target NY-ESO1, developed by Receptor Logic, for cancer treatment. “Our expertise in cancer target identification, when coupled with our development of TCRm monoclonal antibodies to cancer targets, provides a powerful pipeline for immuno-oncology drug development,”...